Bacopa Monnieri

—

evidence score

nootropic

brahmiwater hyssopbacopa+2 more

Bacopa monnieri is an Ayurvedic herb with the strongest human evidence for long-term memory consolidation of any supplement. Multiple meta-analyses (12+ RCTs) confirm improvements in free recall, attention, and processing speed. Critically, the mechanism is slow — effects require 8-12 weeks of daily use to peak, as bacosides must remodel dendritic branching and acetylcholinesterase expression. CDRI-08 (standardized to 55% bacoside A and B) and Synapsa are the most validated extracts. Bacopa is notable for being an anxiolytic that improves cognition simultaneously — most anxiolytics impair cognition.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

450 mg

300 mgRange900 mg

Frequencydaily

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~3-4 hours; bacoside tissue effects weeks

OnsetInitial effects 4 weeks; significant memory improvement 8-12 weeks

DurationEffects peak at 12 weeks; persist during supplementation

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Bacopa Monnieri is currently categorized as a nootropic compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Bacosides inhibit acetylcholinesterase; induce BDNF and dendrite branching; antioxidant via SOD/CAT induction; serotonin 5-HT3 antagonism; cortisol reduction

Practical Context

Strongest current signals

No indexed study summaries yet.